Recently, polymorphisms in genes involved in activating NF-κB through the Toll-like receptor (TLR) signaling pathways, genes regulating TNF-α signaling, and cytokines regulated by NF-κB are important predictors for the response to anti-TNF-α therapy among patients with IBD [21–23]. Here, TNF is linked to inflammatory bowel disease.